MMJ is one of a few companies that are following FDA guidelines in the development of their pharmaceutical THC, CBD soft-gelatin capsule for human consumption in to be FDA approved clinical trials.
Duane Boise the companies president stated “Following federal guidelines and obtaining FDA approval for such trials is an important milestone in ensuring the safety and efficacy of this new cannabis pharmaceutical product”.
Dr. Elio Mariani stated, “It’s worth noting that while cannabis remains classified as a schedule I controlled substance at the federal level, there has been growing interest in researching its potential medical benefits. In the case of MMJ, the FDA should release its clinical hold for its medicine to be used in clinical trials. MMJ has adhered to the current strict federal regulatory requirements.”
MMJ companies will be the first to enter the market with a whole plant natural extract medicine from the marijuana plant with an FDA approval to conduct human clinical trials in Multiple Sclerosis and Huntington’s Disease.
When MMJ International Holdings receives FDA approval to conduct human clinical trials using its medicine derived from the marijuana plant, it will be a significant development in the field of medical cannabis research and pharmaceuticals.
FUNDING MARIJUANA CLINICAL TRIALS – CANNABIS MEETS CRYPTO – CORRECTION ARTICLE 4/18/23
Earlier this year MMJ entered into an agreement with Global Cannabis Holdings. In an article dated April 18, 2023, we announced a series of activities to be carried out in collaboration with Global Cannabis Holdings. Due to an inadvertent error on the part of Global Cannabis Holdings and David Luftglass, STOKR was referred to as an entity ‘under supervision’ of the CSSF, which is not regulatorily accurate. To clarify: STOKR is a virtual asset service provider (VASP), registered with the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg for AML/CFT supervision”.
